Behavioral Finance

Export Revenue Mix isn't just a percentage — it's a forensic test for customer concentration, currency hedging, and pricing power against global benchmarks. Using Titan Biotech FY25's audited ~34.5% export share across 60+ countries as an educational illustration of disciplined geographic diversification.

A forensic balance-sheet ratio every Indian long-term investor should master, illustrated with Titan Biotech FY25 audited markers (₹11 Cr CWIP, ₹57 Cr Gross Block, ₹3 Cr borrowings, 103% CFO/Operating Profit).

Learn the CFO/EBITDA cash-conversion ratio — the 60-second test that separates real operating profits from accounting fiction — using Titan Biotech FY25's 103% audited reading as a positive illustration.

Ellen Langer's 1975 illusion-of-control experiments explain why 91.1% of Indian F&O traders lose money — and the 8-point counter-measure checklist serious long-term investors must install. Titan Biotech FY25's ₹3 Cr borrowings, 103% CFO/Operating Profit, and 36.4% independent-board ratio illustrate the corporate analogue of the anti-bias discipline (educational case study, not a valuation call).